Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium

NCT01885715 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT01885715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01885715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium
Lead sponsor
Seoul National University Hospital
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2013
Completion date
June 30, 2014
Enrollment
112 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

observation of neuromuscular block